Search results
Results from the WOW.Com Content Network
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
Data source: Ned Davis Research and Hartford Funds. Here are four dividend payers to consider for your long-term stock portfolio: 1. Pfizer. Pfizer (NYSE: PFE) is a more familiar name than it was ...
Pfizer (NYSE: PFE) ranks among healthcare's most reliable dividend payers, but recent struggles have pushed its stock down 13.8% this year. That decline has lifted the yield to an enticing 6.77% ...
Two good examples of stocks that pay more than 6% and can still be ideal long-term options for retirees are Pfizer (NYSE: PFE) and Verizon Communications (NYSE: VZ). Although their yields are high ...
The stock is up 33% year-to-date, its dividend yield is not outlandish in the context of the income-generating tobacco industry, and the company can finance its entire dividend budget with robust ...
Consider, for example, that a study by Hartford Funds and Ned Davis Research found that between 1973 and 2023, companies that grew or initiated dividend payments delivered annualized returns of 10 ...
Here's why they think AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are spectacular high-yield dividend stocks to buy in November. An ideal stock for dividend and ...
Source: Yahoo! Finance. Verizon calling. Verizon looks like the most tempting income-investment option, with a yield that's approaching 7%. The telecom giant hasn't simply trailed the market in ...